Pharma Focus Asia

BioNTech and OncoC4 Announce Strategic Collaboration

Tuesday, March 21, 2023

BioNTech and OncoC4 announced that they have entered into an exclusive worldwide licence and collaboration agreement to develop and commercialise OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.

Under the terms of the agreement, OncoC4 will receive a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties.

  • BioNTech will receive exclusive worldwide licence from OncoC4 to develop and commercialise its anti-CTLA-4 monoclonal antibody candidate, ONC-392
  • BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumour indications, with a randomised Phase 3 trial planned to start in 2023
  • BioNTech also plans to combine ONC-392 with proprietary oncology product candidates to evaluate complementary modes of action with the aim to increase therapeutic effect and unlock larger patient populations

Because of its specific mechanism of action, ONC-392 has the potential to broaden the reach of CTLA-4-targeting immunotherapy. This antibody is a valuable addition to the immuno-oncology portfolio, whether used alone or in combination with personalised immunotherapies.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024